2. Cell Cycle/DNA Damage Cytoskeleton
  3. Kinesin Microtubule/Tubulin
  4. KIF2C-IN-1

KIF2C-IN-1 is a cell-penetrating, selective KIF2C inhibitor with fluorescent properties (Ex/Em = 410/510 nm). KIF2C-IN-1 exhibits notable cytotoxicity and weak inhibitory effects on KIF2A/B. KIF2C-IN-1 prohibits the dissociation of KIF2C from microtubules. KIF2C-IN-1 inhibiting KIF2C reverses cross-resistance to microtubule-targeting agents. KIF2C-IN-1 reduces tumorigenesis in chemoresistant triple-negative breast cancer (TNBC) model in mice with the combination of Paclitaxel (HY-B0015).

For research use only. We do not sell to patients.

KIF2C-IN-1

KIF2C-IN-1 Chemical Structure

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

KIF2C-IN-1 Related Antibodies

Top Publications Citing Use of Products

View All Kinesin Isoform Specific Products:

View All Isoforms
Kinesin-5/Eg5/KSP Kinesin-6 Kinesin-7/CENP-E Kinesin-12 Kinesin-14 Kinesin-13

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

KIF2C-IN-1 is a cell-penetrating, selective KIF2C inhibitor with fluorescent properties (Ex/Em = 410/510 nm). KIF2C-IN-1 exhibits notable cytotoxicity and weak inhibitory effects on KIF2A/B. KIF2C-IN-1 prohibits the dissociation of KIF2C from microtubules. KIF2C-IN-1 inhibiting KIF2C reverses cross-resistance to microtubule-targeting agents. KIF2C-IN-1 reduces tumorigenesis in chemoresistant triple-negative breast cancer (TNBC) model in mice with the combination of Paclitaxel (HY-B0015)[1].

In Vitro

KIF2C-IN-1 (compound 7S9) (50 μM) inhibits KIF2C activity by disrupting its dissociation from MTs[1].
KIF2C-IN-1 (0-200 μM, 30 min) increases the molecular interaction between KIF2C and tubulin in a dose-dependent manner, while KIF2C depletion does not alter poly(E) tubulin levels in 4T1 R4 cells[1].
KIF2C-IN-1 (72 h) exhibits notable cytotoxicity against 4T1 S1, R4, and R8 cells (IC50 values of 6.1 μM, 6.8 μM and 4.9 μM respectively)[1].
KIF2C-IN-1 (10 μM, 72 h) restores MT sensitivity to Paclitaxel (400 nM, 72h) in chemoresistant cells (4T1 R4 and 4T1 R8 cells), reducing Paclitaxel IC50 by 11.8- and 8.2-fold, respectively and increasing their sensitivity by 10.5- and 8-fold[1].
KIF2C-IN-1 (1 μM, 14-30 days) induces substantial mitotic defects only with the combined treatment of Paclitaxel (400 nM, 14-30 days) in 4T1 R4 and R8 cells, including prolonged mitotic progression, cytokinesis failure, and mitotic cell death[1].
KIF2C-IN-1 (2 μM) has a synergistic effect with major types of MTAs in chemoresistant cells, which could be a potential strategy to diminish cross-resistance in TNBC[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

KIF2C-IN-1 Related Antibodies

Cell Viability Assay[1]

Cell Line: 4T1 S1, R4, and R8 cells
Concentration: 2 μM
Incubation Time: 72 h
Result: Enhanced the chemosensitivity of R4 and R8 cells to all tested MTAs (Docetaxel (HY-B0011), Ixabepilone (HY-10222), Eribulin (HY-13442), and Vinorelbine (HY-12053)).
Showed the highest synergistic cytotoxic effect with taxane derivatives (Docetaxel and Paclitaxel), increasing sensitivity by more than 90-fold with a CI below 0.5.
Increased chemosensitivity by at least 20-fold in R4 and R8 cells for Ixabepilone, Eribulin and Vinorelbine, with CI values ranging between 0.46 and 0.54.

Cell Viability Assay[1]

Cell Line: 4T1 R4 and R8 cells
Concentration: 1 μM, Paclitaxel (400 nM)
Incubation Time: 72 h
Result: Reduced the IC50 of Paclitaxel in 4T1 R4 and R8 cells by 11.8- and 8.2-fold.
Exhibited increased potency in the presence of a non-lethal dose of Paclitaxel (400 nM), with R4 and R8 cells showing 10.5- and 8-fold increases in sensitivity.
In Vivo

KIF2C-IN-1 (compound 7S9) (50 mg/kg, i.p., once daily, five days per week, for two consecutive weeks) synergistically enhances the anti-tumor effects of Paclitaxel in both chemosensitive (4T1 S1) and chemoresistant (4T1 R4 and R8 ) cells of BALB/c mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 4T1-derived cells (4T1, 4T1 R4, and 4T1 R8 cells, s.c. in the right flank with 5 x 105 cells) induced female BALB/c mice (9-10 weeks old, 18-22 g)[1]
Dosage: 50 mg/kg, Paclitaxel (5 mg/kg for 4T1, 15 mg/kg for 4T1 R4 and R8)
Administration: Intraperitoneal injection (i.p.), once a day for 5 consecutive days, followed by 2 days of withdrawal
Result: Inhibited tumor growth by 20.3%, 31.3%, and 62.6% in 4T1-cell-derived tumors in mice treated with Paclitaxel, and the combination, respectively.
Reduced tumor growth at 29%, 41.7%, and 70.2% in mice for R4 cells, treated with KIF2C-IN-1, Paclitaxel, and the combination.
Blocked significant tumor growth by 66.2%, co-treated with Paclitaxel in R8 cells.
Molecular Weight

739.23

Formula

C36H39ClN4O9S
Appearance

Solid

Color

Light yellow to yellow

SMILES

ClC1=CC=C(C2C(C(OC(C)C)=O)=C(C)N=C(S/C3=C\C4=CC=C(OCC(N5CCN(CC)CC5)=O)C=C4)N2C3=O)C=C1.OC(/C=C\C(O)=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

DMSO : ≥ 100 mg/mL (135.28 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.3528 mL 6.7638 mL 13.5276 mL
5 mM 0.2706 mL 1.3528 mL 2.7055 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.5 mg/mL (3.38 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.3528 mL 6.7638 mL 13.5276 mL 33.8190 mL
5 mM 0.2706 mL 1.3528 mL 2.7055 mL 6.7638 mL
10 mM 0.1353 mL 0.6764 mL 1.3528 mL 3.3819 mL
15 mM 0.0902 mL 0.4509 mL 0.9018 mL 2.2546 mL
20 mM 0.0676 mL 0.3382 mL 0.6764 mL 1.6909 mL
25 mM 0.0541 mL 0.2706 mL 0.5411 mL 1.3528 mL
30 mM 0.0451 mL 0.2255 mL 0.4509 mL 1.1273 mL
40 mM 0.0338 mL 0.1691 mL 0.3382 mL 0.8455 mL
50 mM 0.0271 mL 0.1353 mL 0.2706 mL 0.6764 mL
60 mM 0.0225 mL 0.1127 mL 0.2255 mL 0.5636 mL
80 mM 0.0169 mL 0.0845 mL 0.1691 mL 0.4227 mL
100 mM 0.0135 mL 0.0676 mL 0.1353 mL 0.3382 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

KIF2C-IN-1 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

KIF2C-IN-1KinesinMicrotubule/TubulinKIF2Ckinesin-13microtubuleMCAKpaclitaxelPaclitaxeltaxolbreast cancertriple-negativeTNBCchemoresistancecross-resistanceBALB/c miceMTAsDHTPInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
KIF2C-IN-1
Cat. No.:
HY-173522
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.